| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,345,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
161,290 |
614,507 |
4,957,633 |
| Total Buy Value |
$0 |
$4,999,990 |
$11,881,994 |
$42,392,668 |
| Total People Bought |
0 |
1 |
3 |
8 |
| Total Buy Transactions |
0 |
1 |
3 |
27 |
| Total Shares Sold |
958,650 |
2,008,650 |
2,016,840 |
2,287,944 |
| Total Sell Value |
$39,017,864 |
$57,917,864 |
$58,054,276 |
$63,362,460 |
| Total People Sold |
3 |
4 |
7 |
8 |
| Total Sell Transactions |
6 |
7 |
10 |
41 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carlyle Genesis Uk Llc |
10% Owner |
– – • |
2022-08-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,960,231 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-07-19 |
4 |
AS |
$16.01 |
$183,271 |
D/D |
(11,444) |
18,273 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-07-19 |
4 |
OE |
$2.90 |
$51,887 |
D/D |
11,444 |
18,281 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-07-14 |
4 |
AS |
$15.13 |
$137,864 |
D/D |
(9,104) |
18,273 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-07-14 |
4 |
OE |
$2.90 |
$18,406 |
D/D |
6,354 |
27,377 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-07-07 |
4 |
AS |
$15.03 |
$145,453 |
D/D |
(9,666) |
21,023 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-07-07 |
4 |
OE |
$2.90 |
$32,401 |
D/D |
7,001 |
27,202 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-06-22 |
4 |
AS |
$15.01 |
$23,198 |
D/D |
(1,545) |
23,688 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-06-22 |
4 |
OE |
$6.37 |
$7,896 |
D/D |
1,239 |
25,233 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-06-17 |
4 |
AS |
$15.03 |
$88,565 |
D/D |
(5,887) |
23,994 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-06-17 |
4 |
OE |
$2.90 |
$18,256 |
D/D |
4,687 |
28,535 |
|
- |
|
| Grant Sean |
Chief Financial Officer |
• – – |
2022-06-15 |
4 |
B |
$13.60 |
$68,004 |
I/I |
5,000 |
992 |
1.99 |
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-05-31 |
4 |
AS |
$15.22 |
$6,086 |
D/D |
(400) |
25,194 |
|
- |
|
| Curley Joanne |
Chief Development Officer |
• – – |
2022-05-31 |
4 |
OE |
$6.37 |
$2,549 |
D/D |
400 |
25,594 |
|
- |
|
| Enright Patrick G |
Director |
– • • |
2022-02-10 |
4 |
B |
$15.00 |
$4,999,995 |
I/I |
333,333 |
3,429,927 |
2.25 |
- |
|
| Tammenoms Bakker Juliet |
10% Owner |
– – • |
2022-02-10 |
4 |
B |
$15.00 |
$4,999,995 |
I/I |
333,333 |
3,429,927 |
1.5 |
- |
|
| Katabi Maha |
Director |
– • • |
2022-02-10 |
4 |
B |
$15.00 |
$3,999,990 |
D/D |
266,666 |
3,181,442 |
3.92 |
- |
|
| Young Joseph R |
SVP, Finance, Chief Acct Offcr |
• – – |
2022-02-06 |
4 |
B |
$7.00 |
$39,998 |
D/D |
5,714 |
22,679 |
2.74 |
- |
|
| Grant Sean |
Chief Financial Officer |
• – – |
2022-02-06 |
4 |
B |
$7.00 |
$99,995 |
D/D |
14,285 |
49,933 |
2.74 |
- |
|
| Tammenoms Bakker Juliet |
10% Owner |
– – • |
2021-05-18 |
4 |
B |
$11.00 |
$9,999,990 |
I/I |
909,090 |
3,096,594 |
1.5 |
- |
|
| Tammenoms Bakker Juliet |
10% Owner |
– – • |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
|
- |
|
| Seidenberg Beth C |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,343,152 |
1,343,152 |
|
- |
|
| Emster Kurt Von |
Director |
– • – |
2021-05-18 |
4 |
B |
$11.00 |
$8,499,997 |
I/I |
772,727 |
2,960,231 |
2.1 |
- |
|
| Emster Kurt Von |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
|
- |
|
| Abingworth Llp |
10% Owner |
– – • |
2021-05-18 |
4 |
B |
$11.00 |
$8,499,997 |
I/I |
772,727 |
2,960,231 |
1.5 |
- |
|
134 Records found
|
|
Page 5 of 6 |
|
|
